Genetic study of hereditary angioedema causes
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study looks for genetic changes that may explain hereditary angioedema (HAE) and how C1 inhibitor (C1INH) works. Your participation may help researchers better understand what causes symptoms and who is affected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (at least 18 years old) or, if you have no symptoms yet, at least 22 years old
- Have a confirmed diagnosis of hereditary angioedema related to C1 inhibitor (C1INH) deficiency, based on genetic testing or lab testing showing low C1INH function (under 50%)
- Have a family history of symptomatic HAE-C1INH (family members with similar symptoms)
- You must be able to sign the consent form and understand the study
- Do not have recurrent swelling episodes that look like “histamine-related” angioedema (for example, swelling that improves with antihistamines, steroid medicines, and/or epinephrine)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study uses a smartphone app to track how hereditary angioedema affects your daily life over 8 weeks. It aims to better understand the real-world burden of the condition and may help improve care.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study looks at how people with hereditary angioedema (HAE) are diagnosed and treated in Egypt. It may help doctors better understand and care for this condition.
This trial tests a plasma-derived C1 esterase inhibitor to treat and prevent acute attacks in people with hereditary angioedema (HAE) types 1 or 2. It aims to see if the medicine can quickly relieve swelling episodes and reduce their frequency.
This study looks at thoughts of suicide in people with hereditary angioedema (HAE), a condition that causes sudden swelling. It aims to understand if and how these thoughts may be linked to the condition, so that better support can be offered.
Hear when a new Hereditary Angioedema With C1 Esterase Inhibitor Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.